Literature DB >> 33684591

Naloxone's role in the national opioid crisis-past struggles, current efforts, and future opportunities.

Alex S Bennett1, Luther Elliott2.   

Abstract

Over the past 25 years, naloxone has emerged as a critical lifesaving overdose antidote. Public health advocates and community activists established early methods for naloxone distribution to people who inject drugs, but a legacy of stigmatization and opposition to universal naloxone access continues to limit the drug's full potential to reduce opioid-related mortality. The establishment of naloxone distribution programs under the umbrella of syringe exchange programs faces the same practical, ideological and financial barriers to expansion similar to those faced by syringe exchange programs themselves. The expansion of naloxone from the confines of a few syringe exchange programs to what we see today represents an enormous triumph for the grass-roots activists, service providers, and public health professionals who have fought to guarantee lay access to naloxone. Despite the extensive efforts to expand access to naloxone, naloxone continues to remains a scarce resource in many US localities. Considerable naloxone "deserts" remain and even where there is naloxone access, it does not always reach those at risk. Promising areas for expansion include the development of more robust telehealth methods for naloxone distribution, including subsidized mail delivery programs; lowering barriers to pharmacy access; working with hospitals, ambulances, and law enforcement to expand naloxone "leave behind" programs; providing naloxone co-prescription with medications for opioid use disorder; and working with prisons, shelters, and networks of people who use drugs to increase access to the lifesaving medication. Efforts to ensure over-the-counter and low- or no-cost naloxone are ongoing and stand alongside medication-assisted treatments as efficacious, readily-actionable, and cost-efficient population-level interventions available for combatting opioid-related overdose in the United States.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33684591      PMCID: PMC8327685          DOI: 10.1016/j.trsl.2021.03.001

Source DB:  PubMed          Journal:  Transl Res        ISSN: 1878-1810            Impact factor:   10.171


  127 in total

1.  Gen-X junkie: ethnographic research with young White heroin users in Washington, DC.

Authors:  T G Pierce
Journal:  Subst Use Misuse       Date:  1999-12       Impact factor: 2.164

2.  The ratio of non-fatal to fatal heroin overdose.

Authors:  Shane Darke; Richard P Mattick; Louisa Degenhardt
Journal:  Addiction       Date:  2003-08       Impact factor: 6.526

3.  Emergency Department-based Opioid Harm Reduction: Moving Physicians From Willing to Doing.

Authors:  Elizabeth A Samuels; Kristin Dwyer; Michael J Mello; Janette Baird; Adam R Kellogg; Edward Bernstein
Journal:  Acad Emerg Med       Date:  2016-03-22       Impact factor: 3.451

4.  Evaluation of an Unsanctioned Safe Consumption Site in the United States.

Authors:  Alex H Kral; Barrot H Lambdin; Lynn D Wenger; Pete J Davidson
Journal:  N Engl J Med       Date:  2020-07-08       Impact factor: 91.245

5.  Identifying gaps in the implementation of naloxone programs for laypersons in the United States.

Authors:  Barrot H Lambdin; Jon Zibbell; Eliza Wheeler; Alex H Kral
Journal:  Int J Drug Policy       Date:  2017-12-09

6.  Life after opioid-involved overdose: survivor narratives and their implications for ER/ED interventions.

Authors:  Luther Elliott; Alex S Bennett; Brett Wolfson-Stofko
Journal:  Addiction       Date:  2019-04-11       Impact factor: 6.526

7.  Barriers to naloxone use and acceptance among opioid users, first responders, and emergency department providers in New Hampshire, USA.

Authors:  Sarah Bessen; Stephen A Metcalf; Elizabeth C Saunders; Sarah K Moore; Andrea Meier; Bethany McLeman; Olivia Walsh; Lisa A Marsch
Journal:  Int J Drug Policy       Date:  2019-10-04

8.  Saved by the nose: bystander-administered intranasal naloxone hydrochloride for opioid overdose.

Authors:  Maya Doe-Simkins; Alexander Y Walley; Andy Epstein; Peter Moyer
Journal:  Am J Public Health       Date:  2009-05       Impact factor: 9.308

9.  The protective effect of trusted dealers against opioid overdose in the U.S.

Authors:  Jennifer J Carroll; Josiah D Rich; Traci C Green
Journal:  Int J Drug Policy       Date:  2020-03-04

10.  Delivering Opioid Overdose Prevention in Bars and Nightclubs: A Public Awareness Pilot in New York City.

Authors:  Bennett Allen; Laura Sisson; Jennifer Dolatshahi; Jaclyn Blachman-Forshay; Ariel Hurley; Denise Paone
Journal:  J Public Health Manag Pract       Date:  2020 May/Jun
View more
  5 in total

1.  Fentanyl Test Strip Use and Overdose History among Individuals on Medication for Opioid Use Disorder.

Authors:  C B Mistler; A O Rosen; W Eger; M M Copenhaver; R Shrestha
Journal:  Austin J Public Health Epidemiol       Date:  2021-12-29

Review 2.  U.S. Military veterans and the opioid overdose crisis: a review of risk factors and prevention efforts.

Authors:  Alex S Bennett; Honoria Guarino; Peter C Britton; Dan O'Brien-Mazza; Stephanie H Cook; Franklin Taveras; Juan Cortez; Luther Elliott
Journal:  Ann Med       Date:  2022-12       Impact factor: 5.348

3.  The COVID-19 pandemic and the health of people who use illicit opioids in New York City, the first 12 months.

Authors:  Alex S Bennett; Tarlise Townsend; Luther Elliott
Journal:  Int J Drug Policy       Date:  2021-12-01

4.  Naloxone protection, social support, network characteristics, and overdose experiences among a cohort of people who use illicit opioids in New York City.

Authors:  Alex S Bennett; Joy Scheidell; Jeanette M Bowles; Maria Khan; Alexis Roth; Lee Hoff; Christina Marini; Luther Elliott
Journal:  Harm Reduct J       Date:  2022-03-04

5.  Perspectives from law enforcement officers who respond to overdose calls for service and administer naloxone.

Authors:  Hope M Smiley-McDonald; Peyton R Attaway; Nicholas J Richardson; Peter J Davidson; Alex H Kral
Journal:  Health Justice       Date:  2022-02-25
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.